VREOF (Vireo Growth) 6-Month Price Index: 0.75 (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VREOF Vireo Growth Inc VREOF
47 GF Score
Price $10.86
GF Value $11.66
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Vireo Growth 6-Month Price Index?

Vireo Growth VREOF +0.20% 47 6-Month Price Index is 0.75 as of Aug. 21, 2026. GuruFocus rates VREOF with a GF Score™ of 47/100 and a GF Value™ of $11.66 (Fairly Valued). The stock has 6 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-21), Vireo Growth's 6-Month Price Index is 0.75.


Vireo Growth  (OTCPK:VREOF) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.


Vireo Growth 6-Month Price Index Related Terms


VREOF vs ZTS: 6-Month Price Index Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

VREOF
47GF Score
Vireo Growth Inc VREOF
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vireo Growth  (OTCPK:VREOF) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.75 mean?
Vireo Growth (VREOF) has a 6-Month Price Index of 0.75 as of Aug. 21, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Vireo Growth and its competitors.
Is Vireo Growth's 6-Month Price Index too high?
Vireo Growth's current 6-Month Price Index is 0.75. Overall, Vireo Growth has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's 6-Month Price Index compare to ZTS?
Vireo Growth's 6-Month Price Index of 0.75 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Drug Manufacturers company?
A good 6-Month Price Index depends on the Drug Manufacturers industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Vireo Growth and its competitors. Vireo Growth's current 6-Month Price Index is 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (VREOF) is currently considered Fairly Valued. The stock's GF Value™ is $11.66, compared to a current price of $10.86 — trading 6.9% below its estimated fair value. The current 6-Month Price Index is 0.75. Vireo Growth's overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Vireo Growth (VREOF), the current 6-Month Price Index is 0.75 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vireo Growth (VREOF) Overvalued in 2026?

Based on GuruFocus' analysis, Vireo Growth stock appears to be undervalued. The current stock price of $10.86 is trading 6.9% below its estimated GF Value™ of $11.66. GuruFocus considers Vireo Growth to be Fairly Valued.

Key valuation signals for VREOF:

  • 6-Month Price Index: 0.75
  • GF Value™: $11.66 vs. price of $10.86 (6.9% below fair value)
  • GF Score™: 47/100 with 6 warning signs

No single metric tells the full story. See the VREOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vireo Growth Business Description

Other Exchanges K95:GermanyVREO:Canada
Address 207 South 9th Street, Minneapolis, Minneapolis, MN, USA, 55402
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
47GF Score

Get the complete analysis for VREOF

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.86
Price
$11.66
GF Value